CCL5 (human) (rec.) (His)
|Synonyms||C-C Motif Chemokine 5; Eosinophil Chemotactic Cytokine; EoCP; Small-inducible Cytokine A5; T Cell-specific Protein P228; TCP228; T Cell-specific Protein RANTES|
|Sequence||Human CCL5 (aa 24-91) is fused at the C-terminus to a His-tag.|
|Endotoxin Content||<0.1EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstituted in sterile H2O not less than 100μg/ml, which can then be further diluted in other aqueous solutions.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS (pH 7.4).|
|Other Product Data||NCBI reference AAH08600: CCL5 (human)|
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
CCL5, also known as RANTES (Regulated upon Activation Normal T cell Expressed and Secreted), is an 8kDa β-chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes. Human and mouse RANTES exhibit cross-species activity on human and mouse cells. CCL5 is secreted by many cell types at inflammatory sites and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4 and CCR5. In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1. The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes. CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells and the vasculature.